Target intelligence / Profile preview

Salmonella enterica serovar Enteritidis core-O-polysaccharide (SE COPS)

Target
SE COPS
Molecular classification
Bacterial surface antigen, Polysaccharide, Lipopolysaccharide component
01

Overview

Salmonella enterica serovar Enteritidis core-O-polysaccharide (COPS) is a complex carbohydrate structure located on the outer membrane of the bacterium, representing the combined core oligosaccharide and the O-specific polysaccharide (O-antigen) chain of the lipopolysaccharide (LPS) molecule (Simon et al., 2011). The O-antigen portion consists of repeating units of mannose, rhamnose, and galactose, with a characteristic tyvelose side chain that defines the O9 serogroup specificity (Liu et al., 2014). Biologically, COPS is essential for maintaining the structural integrity of the bacterial outer membrane and serves as a primary defense mechanism against host innate immunity, particularly the complement system (MacLennan et al., 2014). In the field of vaccinology, COPS is a major therapeutic target for preventing invasive non-typhoidal Salmonella (iNTS) infections and foodborne gastroenteritis (Micoli et al., 2018). It is typically developed as a glycoconjugate vaccine, where the COPS is chemically linked to a carrier protein like CRM197 or tetanus toxoid to induce a robust, T-cell dependent antibody response (Tennant et al., 2016). These antibodies facilitate the clearance of the pathogen through opsonophagocytosis and serum bactericidal activity.

Other names
Salmonella Enteritidis O-antigenGroup D1 O-antigenSalmonella Enteritidis LPS O-side chainO9 antigenSE COPS
02

Mechanism of action

Induction of protective humoral immunity, specifically opsonophagocytic and bactericidal antibodies against the O-antigen

03

Biological functions

Immune evasionStructural integrity of the outer membraneProtection against complement-mediated lysisBacterial serotype specificityResistance to environmental stress
04

Disease associations

InfectionSalmonellosisGastroenteritisBacteremiaFoodborne illness
05

Safety considerations

Risk of residual endotoxicity if Lipid A is not completely removed during purificationSerotype-specific immunity (lack of cross-protection against other serovars like Typhimurium)Potential for immune interference in multivalent vaccine formulationsPoor immunogenicity of pure polysaccharide in infants requiring protein conjugation
06

Interacting drugs

Salmonella Enteritidis COPS-CRM197 conjugate vaccine

3 more in the full profile.

07

Biomarkers

Anti-O9 IgG antibody titerSerum bactericidal activity (SBA) titerOpsonophagocytic activity (OPA) titerAnti-Salmonella Enteritidis COPS IgG levels

Beyond the preview

Go deeper on Salmonella enterica serovar Enteritidis core-O-polysaccharide (SE COPS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Salmonella enterica serovar Enteritidis core-O-polysaccharide (SE COPS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call